Royalty Pharma plc (RPRX) earnings date
Feb 10, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 3 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | before open | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 11, 2026 | before open | 42 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | before open | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Tue, Feb 11, 2025 | before open | 42 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Press Release November 4, 2026 R oyalty Pharma reports third quarter 2026 results Portfolio Rece ipts growth o f 9% to $890 million ; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, NY, November 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts." exhibit |
| Q3 FY2026 | "“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board." exhibit |
| Q3 FY2026 | "Raising financial guidance for full year 2026 (excludes contribution from future transactions)" exhibit |
| Q3 FY2026 | "Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,500 million and $3,550 million (previously $3,400 million to $3,500 million), representing expected Royalty Receipts growth of 10% to 11%." exhibit |
| Q3 FY2026 | "Royalty Pharma Press Release | November 4, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows: Provided November 4, 2026 Previous Portfolio Receipts $3,500 million to $3,550 million $3,400 million to $3,500 million Payments for operating and professional costs 5.5% to 6.0% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and " exhibit |
| Q2 FY2026 | "Document Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised f ull year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million NEW YORK, NY, August 5, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts." exhibit |
| Q2 FY2026 | "Raising financial guidance for full year 2026 (excludes contribution from future transactions)" exhibit |
| Q2 FY2026 | "Royalty Pharma now expects 2026 Portfolio Receipts to be between $3,400 million and $3,500 million (previously $3,325 million to $3,450 million), representing expected Royalty Receipts growth of 7% to 10%." exhibit |
| Q2 FY2026 | "Royalty Pharma Press Release | August 5, 2026 1 2026 Financial Outlook Royalty Pharma has provided guidance for full year 2026, excluding new transactions and borrowings announced after the date of this release, as follows: Provided August 5, 2026 Previous Portfolio Receipts $3,400 million to $3,500 million $3,325 million to $3,450 million Payments for operating and professional costs 5.5% to 6.5% of Portfolio Receipts 5.5% to 6.5% of Portfolio Receipts Interest paid $350 million to $360 million $350 million to $360 million Portfolio Receipts is defined as the sum of Royalty Receipts and Miles" exhibit |
| Q2 FY2026 | "The above Portfolio Receipts guidance provided on August 5, 2026 includes expected Royalty Receipts growth of 7% to 10% in 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RPRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RPRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RPRX/"><img src="https://veritasdata.dev/embed/RPRX.svg" alt="RPRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RPRX/)
Script
<script async src="https://veritasdata.dev/embed/RPRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RPRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.